The company has been pushing for more reimbursement of its three marketed DTx products in the US following a first FDA approval in 2017.
Pear said that the Ohio Department of Mental Health and Addiction Services (OhioMHAS) and RecoveryOhio are providing access to Pear’s FDA-approved DTx reSET and reSET‑O, for treatment of substance use disorder and opioid use disorders, respectively. [Read more…] about Ohio joins Indiana and Kentucky in funding Pear Therapeutics’ digital addiction treatments
Pear Therapeutics raises $80M in push for reimbursement (MedCity News):
Pear Therapeutics raised $80 million in funding, which it plans to use as part of a push for coverage of its digital therapeutics. The Boston-based company has three FDA-cleared products, including digital therapeutics for substance use disorder, opioid use disorder, and most recently, insomnia. [Read more…] about Pear Therapeutics raises $80M; finds cost savings of $2,150 per patient with opioid use disorder
“Boston- and San Francisco-based Pear Therapeutics, maker of a prescription digital therapeutic platform, announced today the closure of $50 million in Series B funding. The round was led by Singapore-based investment company Temasek, with participation from returning investors 5AM Ventures, Arboretum Ventures, and JAZZ Venture Partners, as well as new partners Novartis, EDBI, and the Bridge Builder’s Collaborative [Read more…] about Pear Therapeutics raises $50M to develop and market a portfolio of digital therapeutics for mental health